Group 1 - The core viewpoint of the article is that Yifang Biotechnology (Shanghai) Co., Ltd. plans to utilize part of its idle raised funds for cash management to enhance fund efficiency and returns for the company and its shareholders [1][2][5] Group 2 - The total amount of raised funds is RMB 208,380 million, with an issuance price of RMB 18.12 per share, approved by the China Securities Regulatory Commission on April 1, 2022 [1] - The company intends to use up to RMB 1 billion of temporarily idle raised funds for cash management, with a validity period of 12 months from the approval date by the board of directors [2] - The investment products will include low-risk, high-liquidity financial products such as structured deposits, time deposits, and large certificates of deposit, with a maximum investment period of 12 months [2] Group 3 - The decision to use idle funds for cash management was approved in the fifth meeting of the second board of directors on August 21, 2025, ensuring that it will not affect the normal operation of the company's main business or the progress of investment projects [2][4] - The company has established a robust approval and execution process for purchasing cash management products to ensure fund safety, including the use of dedicated settlement accounts [3][4] Group 4 - The sponsor, CITIC Securities, has verified that the company has followed necessary decision-making procedures and complies with relevant laws and regulations regarding the use of idle raised funds for cash management [5][6]

证券代码：603983 证券简称：丸美生物 公告编号：2025-022 广东丸美生物技术股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"或"丸美生物"）于 2025 年 8 月 21 日召开了第五届董事会第七次会议，审议通过了《关于使用部分闲置 募集资金进行现金管理的议案》，拟使用不超过人民币 20,000 万元的闲置募集 资金进行现金管理，该额度可滚动使用，自公司第五届董事会第七次会议审议通 过之日起十二个月内有效，并提请授权管理层行使决策权并签署相关合同文件， 具体事项由公司财务部负责组织实施。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》（证监许可[2019]917 号）核准，并经上海证券交易所同 意，丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为 每股人民币 20.54 元。共计募集资金人民币 84,214.00 万 ...

Meeting Overview - The fifth meeting of the board of directors of Guangdong Marubi Biotechnology Co., Ltd. was held on August 21, 2025, with all 9 directors present [1] - The meeting was convened in compliance with relevant laws and regulations, and the resolutions passed are legally valid [1] Resolutions Passed - All resolutions were approved with 9 votes in favor, 0 against, and 0 abstentions [2][3] - The resolutions included the approval of the 2025 semi-annual report and the special report on the use of raised funds [2] Financial Decisions - The company and its subsidiaries are authorized to apply for a comprehensive credit limit of up to 1.2 billion RMB for various financing activities [3] - A cash dividend of 2.50 RMB (including tax) per 10 shares will be distributed to shareholders based on the total share capital on the record date [3] Upcoming Events - The company will hold its first extraordinary general meeting of 2025 to review the proposed resolutions [4]

南京国博电子股份有限公司（以下简称"公司"）第二届监事会第六次会议 于 2025 年 8 月 22 日以通讯方式召开，会议通知及资料于 2025 年 8 月 15 日以电 子邮件形式送达公司全体监事。本次会议由公司监事会主席孙博女士召集和主 持，会议应出席监事 3 人，实际到会监事 3 人。本次会议的召集、召开及表决符 合有关法律、法规和《南京国博电子股份有限公司章程》的规定，作出的决议合 法、有效。 二、监事会会议审议情况 证券代码：688375 证券简称：国博电子 公告编号：2025-028 南京国博电子股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 经与会监事审议表决，形成会议决议如下： （一）审议通过《关于公司使用部分闲置募集资金进行现金管理的议案》 经审查，监事会认为：公司本次使用部分闲置募集资金不超过 44,100.00 万元（含本数）进行现金管理，内容及审议程序符合《上市公司募集资金监管规 则》《上海证券交易所科创板上市公司自律监管指引第 ...

2025年8月22日，*ST松发（603268）七届董事会一次会议通过议案，同意在不影响募投项目、确保资 金安全前提下，用不超5亿元暂时闲置募集资金进行现金管理，购买保本型储蓄产品，期限12个月，资 金可循环使用；同时以协定存款方式存放本次定增配套资金。公司此次募资净额39.32亿元，已对募投 项目投资额调整。 ...

Group 1 - The board meeting was held on August 20, 2025, with all 7 directors present, and the meeting complied with relevant laws and regulations [1][2] - The board approved the use of raised funds to replace self-raised funds used for project investments and issuance expenses, totaling 264,100 RMB (excluding VAT) [1][2] - The board agreed to use up to 330 million RMB of idle raised funds for cash management, focusing on low-risk, high-liquidity financial products with a maximum investment period of 12 months [2][3] Group 2 - The board approved the temporary use of up to 100 million RMB of idle raised funds to supplement working capital, limited to operations related to the main business, with a maximum usage period of 12 months [3][4] - The board agreed to use self-owned funds and bank acceptance bills to pay for project expenses, with plans to replace these with raised funds later [4][5] - The board unanimously agreed to hold the second temporary shareholders' meeting on September 8, 2025 [5]

证券代码：300539 证券简称：横河精密 公告编号：2025-040 宁波横河精密工业股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 （一）本次监事会会议由监事会主席胡赞文先生召集，会议通知于 2025 年 召开时间、地点、内容和方式。 （二）本次监事会于 2025 年 8 月 20 日在宁波横河精密工业股份有限公司 （以 下简称"公司"）会议室召开，本次会议采用现场和通讯相结合的出席及表决方 式。 （三）本次监事会应出席监事 3 人，实际出席监事 3 人。 （四）本次监事会由监事会主席胡赞文先生主持，董事会秘书胡建锋先生列 席了本次监事会。 具体内容详见公司同日于指定信息披露媒体《证券时报》及巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用募集资金置换预先投入募投项目及已支 付发行费用的自筹资金的公告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票，本议案获得通过。 （二）审议通过《关于使用部分闲置募集资金进行现金管理的议案》 经审议，监事会同意公司在不影响募集资金投资项目建设和公司正常经营的 ...

Summary of Key Points Core Viewpoint - The company intends to utilize part of its idle raised funds for cash management to enhance fund efficiency while ensuring that it does not affect the ongoing investment projects and complies with relevant regulations [2][7][8]. Group 1: Fundraising Overview - The company issued 45,300,462 A shares at a price of 12.98 RMB per share, raising a total of approximately 588 million RMB, with a net amount of about 583 million RMB after deducting issuance costs [2][4]. - The funds have been deposited into a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the bank and the sponsor [2][4]. Group 2: Investment Project Details - The total investment for the projects funded by the raised capital is approximately 593.56 million RMB, with about 588 million RMB planned to be allocated from the raised funds [4]. Group 3: Cash Management Plan - The company plans to use up to 330 million RMB of idle raised funds for cash management within a 12-month period, allowing for rolling use of the funds [5][6]. - The cash management will focus on low-risk, high-security financial products with a maximum investment term of 12 months, including fixed deposits and structured deposits [5][6]. Group 4: Decision-Making Process - The board of directors and the supervisory board have approved the cash management plan, confirming that it aligns with regulatory requirements and benefits all shareholders [7][8].

Core Viewpoint - The report provides a detailed account of the fundraising activities and the actual usage of the raised funds by Shanxi Huaxiang Group Co., Ltd. for the first half of 2025, highlighting the amounts raised, expenses incurred, and the allocation of funds to various projects [1][2][4]. Fundraising Overview - The company raised a total of RMB 800 million through convertible bonds, with a net amount of RMB 786.51 million after deducting related expenses of RMB 13.49 million [1]. - The company also issued 26,649,746 shares of common stock, raising a net amount of RMB 20.74 million after deducting issuance costs [1]. Fund Usage and Balance - As of June 30, 2025, the total amount of funds used was RMB 707.42 million, with a remaining balance of RMB 76.35 million [1][2]. - The breakdown of fund usage includes project investments totaling RMB 607.22 million and interest income of RMB 3.73 million [1][2]. Fund Management - The company has established a fundraising management system to ensure the effective use of funds, including the opening of dedicated bank accounts and signing of tripartite and quadripartite supervision agreements with banks and sponsors [2]. - As of June 30, 2025, the company maintained 10 dedicated fundraising accounts with a total balance of RMB 76.35 million [2]. Actual Fund Usage in 2025 - The company reported no abnormal situations in the usage of the raised funds for investment projects, with a focus on alleviating cash flow pressure and reducing financial risks [2][4]. - The company has also approved the use of idle funds for cash management, allowing for temporary investments in financial products, with a total of RMB 4.05 billion allocated for this purpose [2][4]. Project Status and Adjustments - The company has decided to extend the timeline for certain projects, including the "Machining Expansion and Component Industry Chain Extension Project" and the "Intelligent Upgrade of Casting Production Line," to December 2025 due to external market conditions [4][6]. - The adjustments in project funding and implementation have been approved by the board and are in compliance with regulatory requirements [6].

Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management to enhance fund efficiency and returns without affecting its main business operations [1][2][5]. Summary by Sections 1. Basic Situation of Raised Funds - The company has received approval from the China Securities Regulatory Commission to issue 12,147,560 convertible bonds, with a total net raised amount of approximately RMB 1.21 billion after deducting issuance costs [1]. - All raised funds are stored in a special account managed according to relevant regulations to protect investor interests [1]. 2. Investment Projects of Raised Funds - The raised funds will primarily be allocated to the construction of the Changsha Cybersecurity and Cloud Computing R&D Base, with a total investment of RMB 2.12 billion, of which RMB 1.21 billion will be funded by the raised capital [2]. 3. Cash Management of Idle Funds - The company intends to use up to RMB 300 million of idle raised funds for cash management, focusing on safe and liquid principal-protected products [3][4]. - The investment decision will be valid for 12 months from the date of approval [4]. 4. Approval Procedures and Opinions - The board of directors approved the cash management proposal on August 20, 2025, confirming that it will not affect the normal operation of the company's investment projects [5]. - The supervisory board supports the decision, stating it will enhance fund efficiency and will not harm the interests of the company or minority shareholders [5]. 5. Sponsor's Verification Opinion - The sponsor confirms that the cash management plan has undergone necessary approval processes and complies with relevant laws and regulations, ensuring it does not change the intended use of raised funds [6].